Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal Bevacizumab and Chemotherapy for Malignant Peritoneal Adhesion in Ovarian Cancer
NCT03095001Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2017
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in Peritoneal adhesions (ARD), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
Peritoneal adhesions (ARD)
Beyond the preview
Go deeper on NCT03095001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095001.